特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
960538

ワクチンの世界市場・技術 - COVID-19の影響を含む:2028年までの予測

Global Vaccines - Market and Technology Forecast to 2028: COVID-19 included Market Forecasts by Region, by Technology, by Type, Current Market Overview, Market Trends and Leading Company Profiles

出版日: | 発行: Market Info Group | ページ情報: 英文 274 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
ワクチンの世界市場・技術 - COVID-19の影響を含む:2028年までの予測
出版日: 2020年06月12日
発行: Market Info Group
ページ情報: 英文 274 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

ワクチンの総合市場は、2020年の約750億米ドルから、2028年までに約1,230億米ドルに達すると予測されています。市場のCAGRは約6.4%とされています。

当レポートでは、世界のワクチン市場について調査分析し、市場概要、技術動向、市場分析、機会分析、主要企業などについて、体系的な情報を提供しています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 世界のワクチン市場の現在の市場概要

  • 市場概要
  • ワクチン接種の簡単な歴史
  • ワクチンの防御メカニズム
  • ワクチンの分類
  • ワクチンの構成
  • ワクチンで予防できる疾患

第4章 世界のワクチン市場の現在の市場動向

  • ワクチン開発・試験・規制の段階
  • ワクチン開発のステークホルダー
  • ワクチン導入オプション
  • COVID-19ワクチン

第5章 市場技術

  • 逆ワクチン学
  • 構造ワクチン学
  • 免疫予防:遺伝子導入別
  • プレフィルドADインジェクションデバイス
  • 無針ワクチンデリバリー
  • ナノパッチ技術
  • すぐに使える不活化ワクチン
  • 粘膜ワクチン
  • 合成抗原ワクチン
  • DNAワクチン

第6章 市場力学

  • 促進要因
  • 抑制要因
  • 課題
  • PEST
  • ポーターのファイブフォース分析

第7章 国別分析

  • 米国
  • カナダ
  • フランス
  • 英国
  • イタリア
  • ドイツ
  • オーストラリア
  • インド
  • エジプト
  • 南アフリカ

第8章 世界のワクチン市場予測:地域別

  • 世界の総合市場:地域別
  • 世界のワクチン総合市場:地域別(疾患の兆候別)
    • 北米
    • 欧州
    • アジア太平洋
    • 中東
    • ラテンアメリカ
    • その他の地域
  • 世界の総合市場:地域別(患者タイプ別)
    • 北米
    • 欧州
    • アジア太平洋
    • 中東
    • ラテンアメリカ
    • その他の地域

第9章 世界のワクチン市場予測:技術別

  • 世界の総合市場:技術別
  • 世界の総合市場:技術別(タイプ別)
    • 共役ワクチン
    • 不活化・サブユニットワクチン
    • 弱毒化生ワクチン
    • 組換えワクチン
    • トキソイドワクチン
  • 世界の総合市場:技術別(投与モード別)
    • 共役ワクチン
    • 不活化・サブユニットワクチン
    • 弱毒化生ワクチン
    • 組換えワクチン
    • トキソイドワクチン

第10章 世界のワクチン市場予測:患者タイプ別

  • 世界のワクチン総合市場:患者タイプ別
  • 世界のワクチン総合市場:患者タイプ別(技術別)
    • 小児患者
    • 成人患者
  • 世界のワクチン総合市場:患者タイプ別(投与モード別)
    • 小児患者
    • 成人患者

第11章 ワクチン市場に対するコロナの影響

  • イントロダクション
  • コロナシナリオ1
  • コロナシナリオ2
  • コロナシナリオ3

第12章 シナリオ分析

  • イントロダクション
  • シナリオ分析1
  • シナリオ分析2

第13章 機会分析

  • 地域別
  • 技術別
  • 患者タイプ別

第14章 企業のプロファイル

  • Pfizer
  • Sanofi
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • Merck & Co.
  • Novavax
  • CSL Limited
  • AstraZeneca
  • Inovio Pharmaceuticals
  • Emergent BioSolutions

第15章 戦略的結論

第16章 付録

第17章 Market Info Groupについて

目次
Product Code: MIG200776

The Vaccine protects children from severe disease and vaccine-preventable disease complications that can include limb paralysis, hearing loss, epilepsy, brain injury, and death. A child with a vaccine-preventable disease can be denied school attendance or childcare facilities. Consequently, getting vaccinated against these diseases is a good investment and usually includes insurance cover. The Vaccinations for Children program is a federally funded initiative that provides vaccinations for low-income households at no cost to children.

The rapidly increasing rate of COVID-19 infection worldwide in early 2020 prompted international partnerships and policy efforts to urgently mobilize resources to manufacture multiple vaccines on shorter timetables, with around 159 candidate vaccines examined under various levels of clinical trials. There are multiple teams working on a coronavirus vaccine, with a hope that multiple vaccines can be approved at record speed. Billions of doses are needed to be produced, which implies cooperation is crucial between industry, regulators, and the scientific community. The vaccine must be available in all parts of the world to ensure that there is no virus reservoir left.

The total market for the vaccine is estimated at around USD 75 Billion in 2020 and the market is expected to grow to around USD 123 Billion by 2028. The CAGR of the market is accounted for at around 6.4%. By patient type, the vaccine market for pediatric patients is expected to account for the largest share due to the increased collaboration by government and non-government organizations for effective vaccine coverage, mandating the use of vaccines for certain infectious diseases.

Scope:

The study period of the report "Global vaccines- Market and Technology Forecast to 2028" is from 2018-2028, and the forecast period of the report is from 2020-2028.

The report is aimed at:

  • The Key drivers, restraints and challenges which are expected to shape the Global Vaccines market are covered in detailed in the report.
  • The key technologies which could have an impact on the Vaccine Market have been covered in detail.
  • The top ten countries have been analyzed in detail with respect to their size of economy, overview of Healthcare sector and government expenditure (2015-2018), preparedness on the epidemics such as SARS, H1H1, COVID-19, country wise Vaccination coverage.
  • The Porter's Five Forces and the PEST of the Global Vaccines market have been covered in the report.
  • The high growth markets have been identified in the Opportunity Analysis Chapter.
  • The market has been forecasted from 2020- 2028 considering all the factor, which is expected to impact the market.
  • The Scenario Analysis Chapter covers the key scenarios and its impacts on the forecast chapter.

Segmentation covered in this report:

The market is segmented based on End User, Region, Patient Type, and Technology:

By Patient Type

  • Pediatric Patients
  • Adult Patients

Region Wise Segmentation:

  • North America
  • Europe
  • APAC
  • Middle East
  • LATAM
  • ROW

By Technology

  • Conjugate vaccines
  • Inactivated and subunit vaccines
  • Live attenuated vaccines
  • Recombinant vaccines
  • Toxoid vaccines

Country Level Analysis

  • USA
  • France
  • UK
  • Germany
  • Italy
  • Australia
  • Canada
  • India
  • Egypt
  • South Africa

Reasons to buy :

  • The new players in the Vaccines market and the potential entrants into this market can use this report to understand the key market trends that are expected to shape this market in the next few years.
  • The Market Analysis Chapter cover the Key Drivers, Restraints and Challenges of the Vaccines Report. The PEST and the Porter's five forces are covered in detailed in this report.
  • The key technologies that could impact the Vaccines Market have been covered in detailed, an example is the growing implementation of the Nanopatch technology, used in vaccine delivery.
  • The report can be used by sales and marketing team to formulate their medium- and long-term strategies and to reconfirm their short-term plans.
  • The forecast chapter would help the sales team to formulate their medium-term sales plan.
  • The report would be help to the sales and the marketing team to understand the key segments across the top ten countries which have been analyzed in the report.
  • The Opportunity Analysis chapter identifies the key hot spots within the Global Vaccine Market.
  • The company profiles include financials, latest news, contracts, and SWOT for around 10 companies.

Who is this report for?

  • Healthcare professionals: They serve as experts in subject matter throughout most of the process of approval and regulatory oversight.
  • Manufacturers and private industry: The production and testing of a vaccine are costly and full of the potential for liability, ensuring that funding should come from private organizations, such as pharmaceutical firms.
  • Nongovernmental Organizations: They can act as an important gateway between societies and manufacturers to facilitate communication in areas where a vaccine is required.
  • Academy: The academic community performs useful research that can help other stakeholders understand what can be learned about numerous aspects of the development of vaccination. They can promote evidence-based immunization policies, comment on a vaccine's socioeconomic consequences to the population at risk or analyse past studies.
  • Government agencies: In the United States, federal agencies such as the FDA act as the check-and-balance on any vaccine that is made available to consumers.
  • R&D Departments: The R&D departments of vaccine manufacturing companies could use this report to understand the market trends and the vaccine market size.
  • Individuals and communities: The public plays an essential role in assessing vaccine efficacy and safety. From engaging in trials to working as end-users for an approved drug, this group gets down to help recognize the real-world implications of an immunization.
  • Decision Makers: The future investment and technology focus decisions could be formulated based on the inputs of this report.

Table of Contents

1 Introduction

  • 1.1 Objective
  • 1.2 Market Introduction
  • 1.3 Market Scope
  • 1.4 Methodology
  • 1.5 Scenario based Forecast
  • 1.6 Who will benefit from this report?
    • 1.6.1 Business Leaders & Business Developers
    • 1.6.2 Vaccines Professionals
    • 1.6.3 Policy Makers, Budget Planners and Decision Makers
    • 1.6.4 Civil Government Leaders & Planners
    • 1.6.5 Financial analysts, Investors, Consultants
  • 1.7 Language

2 Executive Summary

  • 2.1 Vaccines Market Trends and Insights
  • 2.2 Top Five Major Findings
  • 2.3 Major Conclusion
  • 2.4 Important Tables and Graphs

3 Current Market Overview of Global Vaccines Market

  • 3.1 Market Overview
  • 3.2 A Brief History of Vaccination
  • 3.3 Defense Mechanism of Vaccine
  • 3.4 Classification of Vaccines
    • 3.4.1 Live Attenuated Vaccines
    • 3.4.2 Inactivated Vaccines
  • 3.5 Composition of Vaccines
  • 3.6 Vaccine Preventable Diseases

4 Current Market Trends of the Global Vaccines Market

  • 4.1 Stages of Vaccine Development, Testing, and Regulation
    • 4.1.1 Exploratory Stage
    • 4.1.2 Pre-Clinical Stage
    • 4.1.3 Clinical Development
    • 4.1.4 Vaccine Post-Licensure Monitoring
    • 4.1.5 Manufacturing
  • 4.2 Stakeholders in Vaccine Development
  • 4.3 Vaccine Implementation Options
    • 4.3.1 Implementation and Immunization in the US
    • 4.3.2 Implementation and Immunization in Europe
    • 4.3.3 Implementation and Immunization in Asia-Pacific Region
  • 4.4 COVID 19 Vaccine
    • 4.4.1 Vaccine Production
    • 4.4.2 Technology Platforms
    • 4.4.3 Vaccine Candidates
    • 4.4.4 Partnerships

5 Market Technologies

  • 5.1 Reverse Vaccinology
  • 5.2 Structural Vaccinology
  • 5.3 Immunoprophylaxis by gene transfer
  • 5.4 Prefilled AD Injection Devices
  • 5.5 Needle-free vaccine delivery
  • 5.6 Nanopatch Technology
  • 5.7 Ready-to-use Inactivated Vaccines
  • 5.8 Mucosal Vaccination
  • 5.9 Synthetic Antigen Vaccines
  • 5.10 DNA Vaccines

6 Market Dynamics

  • 6.1 Drivers
    • 6.1.1 Increased incidence of infectious diseases
    • 6.1.2 Government Support in Vaccine Development
    • 6.1.3 Enhanced Vaccine R&D
    • 6.1.4 COVID 19 - Impact on Vaccine Market
  • 6.2 Restraints
    • 6.2.1 Huge Capital Investments with the Vaccine Development
    • 6.2.2 Longer timeline required for vaccine development
  • 6.3 Challenges
    • 6.3.1 Supply chain challenges in temperature-controlled vaccines
    • 6.3.2 Social and Political Negligence
    • 6.3.3 Vaccine Hesitancy
    • 6.3.4 Lack of Vaccine Development Knowledge & Infrastructure
  • 6.4 PEST
    • 6.4.1 Political
    • 6.4.2 Economic
    • 6.4.3 Social
    • 6.4.4 Technology
  • 6.5 Porter's Five Forces
    • 6.5.1 Buyer's Bargaining Power
    • 6.5.2 Suppliers Bargaining Power
    • 6.5.3 Threat of New Entrants
    • 6.5.4 Threat of Substitutes
    • 6.5.5 Rivalry among Competitors

7 Country Analysis

  • 7.1 United States of America (USA)
    • 7.1.1 Introduction
    • 7.1.2 Healthcare Sector
    • 7.1.3 Vaccination coverage in US
  • 7.2 Canada
    • 7.2.1 Introduction
    • 7.2.2 Healthcare Sector
    • 7.2.3 Vaccination Coverage in Canada
  • 7.3 France
    • 7.3.1 Introduction
    • 7.3.2 Healthcare Sector
    • 7.3.3 Vaccination coverage in France
  • 7.4 United Kingdom (UK)
    • 7.4.1 Introduction
    • 7.4.2 Healthcare Sector
    • 7.4.3 Vaccination coverage in United Kingdom
  • 7.5 Italy
    • 7.5.1 Introduction
    • 7.5.2 Healthcare Sector
    • 7.5.3 Vaccination coverage in Italy
  • 7.6 Germany
    • 7.6.1 Introduction
    • 7.6.2 Healthcare Sector
    • 7.6.3 Vaccination coverage in Germany
  • 7.7 Australia
    • 7.7.1 Introduction
    • 7.7.2 Healthcare Sector
    • 7.7.3 Vaccination coverage in Australia
  • 7.8 India
    • 7.8.1 Introduction
    • 7.8.2 Healthcare Sector
    • 7.8.3 Vaccination coverage in India
  • 7.9 Egypt
    • 7.9.1 Introduction
    • 7.9.2 Healthcare Sector
    • 7.9.3 Vaccination coverage in Egypt
  • 7.10 South Africa
    • 7.10.1 Introduction
    • 7.10.2 Healthcare Sector
    • 7.10.3 Vaccination coverage in South Africa

8 Global Vaccines Market Forecast by Region to 2028

  • 8.1 Total Global Market by Region to 2028
  • 8.2 Total Global Vaccines Market by Region (By Disease Indication) to 2028
    • 8.2.1 North America
    • 8.2.2 Europe
    • 8.2.3 APAC
    • 8.2.4 Middle East
    • 8.2.5 LATAM
    • 8.2.6 Rest of the World
  • 8.3 Total Global Market by Region (By Patient Type) to 2028
    • 8.3.1 North America
    • 8.3.2 Europe
    • 8.3.3 APAC
    • 8.3.4 Middle East
    • 8.3.5 LATAM
    • 8.3.6 Rest of the World

9 Global Vaccines Market Forecast by Technology to 2028

  • 9.1 Total Global Market by Technology to 2028
  • 9.2 Total Global Market by Technology (By Type) to 2028
    • 9.2.1 Conjugate Vaccines
    • 9.2.2 Inactivated and subunit Vaccines
    • 9.2.3 Live attenuated Vaccines
    • 9.2.4 Recombinant Vaccines
    • 9.2.5 Toxoid Vaccines
  • 9.3 Total Global Market by Technology (By Mode of Administration) to 2028
    • 9.3.1 Conjugate Vaccines
    • 9.3.2 Inactivated and subunit Vaccines
    • 9.3.3 Live attenuated Vaccines
    • 9.3.4 Recombinant Vaccines
    • 9.3.5 Toxoid Vaccines

10 Global Vaccines Market Forecast by Patient Type to 2028

  • 10.1 Total Global Vaccines Market by Patient Type to 2028
  • 10.2 Total Global Vaccines Market by Patient Type (By Technology) to 2028
    • 10.2.1 Pediatric patients
    • 10.2.2 Adult patients
  • 10.3 Total Global Vaccines Market by Patient Type (By Mode of Administration) to 2028
    • 10.3.1 Pediatric patients
    • 10.3.2 Adult patients

11 Corona Impact on Vaccines Market

  • 11.1 Introduction
  • 11.2 Corona Scenario-1
  • 11.3 Corona Scenario-2
  • 11.4 Corona Scenario- 3

12 Scenario Analysis

  • 12.1 Introduction
  • 12.2 Scenario Analysis 1
  • 12.3 Scenario Analysis 2

13 Opportunity Analysis

  • 13.1 By Region
  • 13.2 By Technology
  • 13.3 By Patient Type

14 Company Profiling

  • 14.1 Pfizer
    • 14.1.1 Company Profile
    • 14.1.2 Products & Services
    • 14.1.3 Segment Revenue
    • 14.1.4 Financial info (revenues, profit last 5 years)
    • 14.1.5 Recent Contract(s) Won
    • 14.1.6 Recent Projects Completed
    • 14.1.7 Strategic Alliances
    • 14.1.8 SWOT Analysis
  • 14.2 Sanofi
    • 14.2.1 Company Profile
    • 14.2.2 Products & Services
    • 14.2.3 Segment Revenue
    • 14.2.4 Financial info (revenues, profit last 5 years)
    • 14.2.5 Recent Contract(s) Won
    • 14.2.6 Recent Projects Completed
    • 14.2.7 Strategic Alliances
    • 14.2.8 SWOT Analysis
  • 14.3 GlaxoSmithKline (GSK)
    • 14.3.1 Company Profile
    • 14.3.2 Products & Services
    • 14.3.3 Segment Revenue
    • 14.3.4 Financial info (revenues, profit last 5 years)
    • 14.3.5 Recent Contract(s) Won
    • 14.3.6 Recent Projects Completed
    • 14.3.7 Strategic Alliances
    • 14.3.8 SWOT Analysis
  • 14.4 Johnson & Johnson
    • 14.4.1 Company Profile
    • 14.4.2 Products & Services
    • 14.4.3 Segment Revenue
    • 14.4.4 Financial info (revenues, profit last 5 years)
    • 14.4.5 Recent Contract(s) Won
    • 14.4.6 Strategic Alliances
    • 14.4.7 SWOT Analysis
  • 14.5 Merck & Co.
    • 14.5.1 Company Profile
    • 14.5.2 Products & Services
    • 14.5.3 Financial info (revenues, profit last 5 years)
    • 14.5.4 Recent Contract(s) Won
    • 14.5.5 Strategic Alliances
    • 14.5.6 SWOT Analysis
  • 14.6 Novavax
    • 14.6.1 Company Profile
    • 14.6.2 Products & Services
    • 14.6.3 Financial info (revenues, profit last 5 years)
    • 14.6.4 Recent Contract(s) Won
    • 14.6.5 Strategic Alliances
    • 14.6.6 SWOT Analysis
  • 14.7 CSL Limited
    • 14.7.1 Company Profile
    • 14.7.2 Products & Services
    • 14.7.3 Financial info (revenues, profit last 5 years)
    • 14.7.4 Recent Contract(s) Won
    • 14.7.5 Strategic Alliances
    • 14.7.6 SWOT Analysis
  • 14.8 AstraZeneca
    • 14.8.1 Company Profile
    • 14.8.2 Products & Services
    • 14.8.3 Financial info (revenues, profit last 5 years)
    • 14.8.4 Recent Contract(s) Won
    • 14.8.5 Strategic Alliances
    • 14.8.6 SWOT Analysis
  • 14.9 Inovio Pharmaceuticals
    • 14.9.1 Company Profile
    • 14.9.2 Products & Services
    • 14.9.3 Financial info (revenues, profit last 5 years)
    • 14.9.4 Recent Contract(s) Won
    • 14.9.5 Strategic Alliances
    • 14.9.6 SWOT Analysis
  • 14.10 Emergent BioSolutions
    • 14.10.1 Company Profile
    • 14.10.2 Products & Services
    • 14.10.3 Financial info (revenues, profit last 5 years)
    • 14.10.4 Recent Contract(s) Won
    • 14.10.5 Strategic Alliances
    • 14.10.6 SWOT Analysis

15 Strategic Conclusions

16 Appendices

  • 16.1 Companies Mentioned
  • 16.2 Abbreviations

17 About Market Info Group

  • 17.1 General
  • 17.2 Contact us

List of tables

  • Table 1: Examples of Vaccines with preservatives, Global Vaccines Market, 2020-2028
  • Table 2: Examples of Adjuvanted Vaccines, Global Vaccines Market, 2020-2028
  • Table 3: Herd Immunity Threshold for some diseases, Global Vaccines Market, 2020-2028
  • Table 4: Key Participants in each COVID 19 Vaccine, Global Vaccines Market, 2020-2028
  • Table 5: Buyer's Bargaining Power, Global Personal Protection Equipment Market, 2020-2028
  • Table 6: Supplier's Bargaining Power, Global Vaccine Market, 2020-2028
  • Table 7: Threat of New Entrants, Global Vaccine Market, 2020-2028
  • Table 8: Threat of Substitutes, Global Vaccine Market, 2020-2028
  • Table 9: Competitive Rivalry, Global Personal Protection Equipment Market, 2020-2028
  • Table 10: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-2028
  • Table 11: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April'2020 data), Global Vaccines Market,2020-2028
  • Table 12: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-2028
  • Table 13: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April'2020 data), Global Vaccines Market,2020-2028
  • Table 14: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-2028
  • Table 15: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April'2020 data), Global Vaccines Market,2020-2028
  • Table 16: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-2028
  • Table 17: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April'2020 data), Global Vaccines Market,2020-2028
  • Table 18: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-2028
  • Table 19: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April'2020 data), Global Vaccines Market,2020-2028
  • Table 20: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-202
  • Table 21: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April'2020 data), Global Vaccines Market,2020-2028
  • Table 22: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-2028
  • Table 23: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April'2020 data), Global Vaccines Market,2020-2028
  • Table 24: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-2028
  • Table 25: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April'2020 data), Global Vaccines Market,2020-2028
  • Table 26: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-2028
  • Table 27: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April'2020 data), Global Vaccines Market,2020-2028
  • Table 28: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-2028
  • Table 29: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April'2020 data), Global Vaccines Market,2020-2028
  • Table 30: Vaccines Market Forecast (Region wise in USD Billion), Global, 2018-2028
  • Table 31: North America Market Forecast (Disease Indication wise in USD Billion), 2018-2028
  • Table 32: Europe Market Forecast (Disease Indication wise in USD Billion), 2018-2028
  • Table 33: APAC Market Forecast (Disease Indication wise in USD Billion), 2018-2028
  • Table 34: Middle East Market Forecast (Disease Indication wise in USD Billion), 2018-2028
  • Table 35: LATAM Market Forecast (Disease Indication wise in USD Billion), 2018-2028
  • Table 36: Rest of the World Market Forecast (Disease Indication wise in USD Billion), 2018-2028
  • Table 37: North America Market Forecast (Patient Type wise in USD Billion), 2018-2028
  • Table 38: Europe Market Forecast (Patient Type wise in USD Billion), 2018-2028
  • Table 39: APAC Market Forecast (Patient Type wise in USD Billion), 2018-2028
  • Table 40: Middle East Market Forecast (Form wise in USD Billion), 2018-2028
  • Table 41: LATAM Market Forecast (Patient Type wise in USD Billion), 2018-2028
  • Table 42: Rest of the World Market Forecast (Patient Type wise in USD Billion), 2018-2028
  • Table 43: Vaccines Market Forecast (Technology wise in USD Billion), Global, 2018-2028
  • Table 44: Conjugate Vaccines Market Forecast (Type wise in USD Billion), Global, 2018-2028
  • Table 45: Inactivated and subunit Vaccines Market Forecast (Type wise in USD Billion), Global, 2018-2028
  • Table 46: Live attenuated Vaccines Market Forecast (Type wise in USD Billion), Global, 2018-2028
  • Table 47: Recombinant Vaccine Market Forecast (Type wise in USD Billion), Global, 2018-2028
  • Table 48: Toxoid Vaccines Market Forecast (Type wise in USD Billion), Global, 2018-2028
  • Table 49: Conjugate Vaccines Market Forecast (Mode of Administration wise in USD Billion), Global, 2018-2028
  • Table 50: Inactivated and subunit Vaccines Market Forecast (Mode of Administration wise in USD Billion), Global, 2018-2028
  • Table 51: Live attenuated Market Forecast (Mode of Administration wise in USD Billion), Global, 2018-2028
  • Table 52: Recombinant Vaccine Market Forecast (Mode of Administration wise in USD Billion), Global, 2018-2028
  • Table 53: Toxoid Vaccines Market Forecast (Mode of Administration wise in USD Billion), Global, 2018-2028
  • Table 54: Vaccines Market Forecast (End-Use Industry wise in USD Billion), Global, 2018-2028
  • Table 55: Pediatic Patients Vaccines Market Forecast (Technology wise in USD Billion), Global, 2018-2028
  • Table 56: Adult Patients Market Forecast (Technology wise in USD Billion), Global, 2018-2028
  • Table 57: Pediatic Patients Market Forecast (Mode of Administration wise in USD Billion), Global, 2018-2028
  • Table 58: Adult Patients Market Forecast (Mode of Administration wise in USD Billion), Global, 2018-2028
  • Table 59: Vaccines Market Forecast (USD Billion), Corona Impact CS-1, 2020-2028
  • Table 60: Vaccines Market Forecast (USD Billion), Corona Impact CS-2, 2020-2028
  • Table 61: Vaccines Market Forecast (USD Billion), Corona Impact CS-3, 2020-2028
  • Table 62: Vaccines market (In USD Billion), Scenario Analysis, 2020-2028
  • Table 63: Vaccines market (In USD Billion), Scenario 1 Analysis, 2020-2028
  • Table 64: Global Vaccines market (In USD Billion), Scenario 1 Factors, 2020-2028
  • Table 65: Vaccines market (In USD Billion), Scenario 1 Analysis, 2020-2028
  • Table 66: Vaccines market (In USD Billion), Scenario 2 Analysis, 2020-2028
  • Table 67: Vaccines market (In USD Billion), Scenario 2 Factors, 2020-2028
  • Table 68: Vaccines market (In USD Billion), Scenario 2 Industry wise Analysis, 2020-2028
  • Table 69: Pfizer Financial Information 2015 - 2019 (USD Billions), Global Vaccines market
  • Table 70: Sanofi Information 2015 - 2019 (USD Billions), Global Vaccines market
  • Table 71: GlaxoSmithKline Financial Information 2015 - 2019 (USD Billions), Global Vaccines market
  • Table 72: Johnson & Johnson Financial Information 2015 - 2019 (USD Billions), Global Vaccines market
  • Table 73: Merck & Co. Financial Information 2015 - 2019 (USD Billions), Global Vaccines market
  • Table 74: Novavax Financial Information 2015 - 2019 (USD Billions), Global Vaccines market
  • Table 75: CSL Limited Financial Information 2015 - 2019 (USD Billions), Global Vaccines market
  • Table 76: AstraZeneca Financial Information 2017 - 2019 (USD Billions), Global Vaccines market
  • Table 77: Inovio Pharmaceuticals Financial Information 2016 - 2019 (USD Billions), Global Vaccines market
  • Table 78: Emergent BioSolutions Financial Information 2015 - 2019 (USD Billions), Global Vaccines market

List of figures

  • Figure 1: Comparison of the Immune Response to a disease-causing Organism and to a Vaccine, Global Vaccines Market, 2020-2028
  • Figure 2: Progress of Polio Elimination 1988 and 2014, Global Vaccines Market, 2020-2028
  • Figure 3: Antibody destruction by antigen, Global Vaccines Market, 2020-2028
  • Figure 4: Live Attenuated Vaccine, Global Vaccines Market, 2020-2028
  • Figure 5: Inactivated Vaccine, Global Vaccines Market, 2020-2028
  • Figure 6: Global Vaccine Coverage in 2018, Global Vaccines Market, 2020-2028
  • Figure 7: Phases of Vaccine Development, Global Vaccines Market, 2020-2028
  • Figure 8: Exploring the drug development process, Global Vaccines Market, 2020-2028
  • Figure 9: Clinical Trials, Global Vaccines Market, 2020-2028
  • Figure 10: Professionals involved in Vaccine Development, Global Vaccines Market, 2020-2028
  • Figure 11: Immunization policy in US, Global Vaccines Market, 2020-2028
  • Figure 12: Immunization in Europe, Global Vaccines Market, 2020-2028
  • Figure 13: Immunization in APAC, Global Vaccines Market, 2020-2028
  • Figure 14: COVID-19 Virus, Global Vaccine Market, 2020-2028
  • Figure 15: Covid 19 Vaccine, Global Vaccine Market, 2020-2028
  • Figure 16: COVID 19- Projected timeline for treatment and prevention, Global Vaccine Market, 2020-2028
  • Figure 17: COVID 19- Possible treatment and prevention, Global Vaccine Market, 2020-2028
  • Figure 18: Reverse Vaccinology - Bexsero(meningococcal group B vaccine), Global Vaccines Market, 2020-2028
  • Figure 19: Structural Vaccinology, Global Vaccine Market, 2020-2028
  • Figure 20: Immunoprophylaxis by gene versus Traditional Passive Immunization, Global Vaccine Market, 2020-2028
  • Figure 21: Activation and use of prefilled bubble-like auto-disable injection, Global Vaccine Market, 2020-2028
  • Figure 22: Needle free vaccine injection, Global Vaccine Market, 2020-2028
  • Figure 23: Cross-section of Nanopatch Technology, Global Vaccine Market, 2020-2028
  • Figure 24: Heartwater disease in animals, Global Vaccine Market, 2020-2028
  • Figure 25: Mucosal Vaccination, Global Vaccine Market, 2020-2028
  • Figure 26: Synthetic Antigen Vaccine, Global Vaccine Market, 2020-2028
  • Figure 27: DNA Vaccine, Global Vaccine Market, 2020-2028
  • Figure 28: Key Drivers, Global Vaccine Market, 2020-2028
  • Figure 29: Global number of Child deaths due to infectious disease, Global Vaccine Market, 2020-2028
  • Figure 30: Global Alliance Partner for Vaccination and Immunization(GAVI) , Global Vaccine Market, 2020-2028
  • Figure 31: Vaccine Ecosystem Interdependancies Chart, Global Vaccine Market, 2020-2028
  • Figure 32: Total confirmed COVID-19 deaths per million people, Global Vaccine Market, 2020-2028
  • Figure 33: Key Restraints, Global Vaccines Market, 2020-2028
  • Figure 34: Vaccine development timeline, Global Vaccine Market, 2020-2028
  • Figure 35: Key Challenges, Global Personal Protection Equipment Market, 2020-2028
  • Figure 36: Percentage of respondents for major challenges to vaccine delivery systems, Global Vaccines Market, 2020-2028
  • Figure 37: Challenges and human responses in Vaccine Development, Global Vaccines Market, 2020-2028
  • Figure 38: Porter's Five Forces, Global Vaccines Market, 2020-2028
  • Figure 39: Epidemic Response Index, Global Vaccines Market,2020-2028
  • Figure 40: Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
  • Figure 41: Incidence of vaccine preventable diseases, Global Vaccines Market,2020-2028
  • Figure 42: Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
  • Figure 43: Epidemic Response Index, Global Vaccines Market,2020-2028
  • Figure 44: Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
  • Figure 45: Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
  • Figure 46: Epidemic Response Index, Global Vaccines Market,2020-2028
  • Figure 47: Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
  • Figure 48: Incidence of vaccine preventable diseases, Global Vaccines Market,2020-2028
  • Figure 49: Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
  • Figure 50: Epidemic Response Index, Global Vaccines Market,2020-2028
  • Figure 51: Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
  • Figure 52: Incidence of vaccine preventable diseases, Global Vaccines Market,2020-2028
  • Figure 53: Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
  • Figure 54: Epidemic Response Index, Global Vaccines Market,2020-2028
  • Figure 55: Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
  • Figure 56: Incidence of vaccine preventable diseases, Global Vaccines Market,2020-2028
  • Figure 57: Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
  • Figure 58: Epidemic Response Index, Global Vaccines Market,2020-2028
  • Figure 59: Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
  • Figure 60: Incidence of vaccine preventable diseases, Global Vaccines Market,2020-2028
  • Figure 61: Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
  • Figure 62: Epidemic Response Index, Global Vaccines Market,2020-2028
  • Figure 63: Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
  • Figure 64: Incidence of vaccine preventable diseases, Global Vaccines Market,2020-2028
  • Figure 65: Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
  • Figure 66: Epidemic Response Index, Global Vaccines Market,2020-2028
  • Figure 67: Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
  • Figure 68: Incidence of vaccine preventable diseases, Global Vaccines Market,2020-2028
  • Figure 69: Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
  • Figure 70: Epidemic Response Index, Global Vaccines Market,2020-2028
  • Figure 71: Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
  • Figure 72: Incidence of vaccine preventable diseases, Global Vaccines Market,2020-2028
  • Figure 73: Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
  • Figure 74: Epidemic Response Index, Global Vaccines Market,2020-2028
  • Figure 75: Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
  • Figure 76: Incidence of vaccine preventable diseases, Global Vaccines Market,2020-2028
  • Figure 77: Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
  • Figure 78: Vaccines Market Forecast (Region wise in USD Billion), Global, 2018- 2028
  • Figure 79: Vaccines Market Forecast (Region wise, In Percent), Global, 2020-2028
  • Figure 80: North America Market Forecast (Disease Indication wise in USD Billion), 2020
  • Figure 81: North America, Vaccines Market Forecast (In Percent), By Disease Indication, 2020-2028
  • Figure 82: Europe Market Forecast (Disease Indication wise in USD Billion), 2020
  • Figure 83: Europe, Vaccine Market Forecast (In Percent), By Disease Indication, 2020-2028
  • Figure 84: APAC Market Forecast (Disease Indication wise in USD Billion), 2020
  • Figure 85: APAC, Vaccines Market Forecast (In Percent), By Disease Indication, 2020-2028
  • Figure 86: Middle East Market Forecast (Disease Indication wise in USD Billion), 2020
  • Figure 87: Middle East, Vaccines Market Forecast (In Percent), By Disease Indication, 2020-2028
  • Figure 88: LATAM Market Forecast (Disease Indication wise in USD Billion), 2020
  • Figure 89: LATAM, Vaccines Market Forecast (In Percent), By Disease Indication, 2020-2028
  • Figure 90: Rest of the World Market Forecast (Disease Indication wise in USD Billion), 2020
  • Figure 91: Rest of the World, Vaccines Market Forecast (In Percent), By Disease Indication, 2020-2028
  • Figure 92: North America Market Forecast (Patient Type wise in USD Billion), 2020
  • Figure 93: North America, Vaccines Market Forecast (In Percent), By Patient Type, 2020-2028
  • Figure 94: Europe Market Forecast (Patient Type wise in USD Billion), 2020
  • Figure 95: Europe, Vaccines Market Forecast (In Percent), By Form, 2020-2028
  • Figure 96: APAC Market Forecast (Patient Type wise in USD Billion), 2020
  • Figure 97: APAC, Vaccines Market Forecast (In Percent), By Patient Type, 2020-2028
  • Figure 98: Middle East Market Forecast (Patient Type wise in USD Billion), 2020
  • Figure 99: Middle East, Vaccines Market Forecast (In Percent), By Patient Type, 2020-2028
  • Figure 100: LATAM Market Forecast (Patient Type wise in USD Billion), 2020
  • Figure 101: LATAM, Vaccines Market Forecast (In Percent), By Patient Type, 2020-2028
  • Figure 102: Rest of the World Market Forecast (Patient Type wise in USD Billion), 2020
  • Figure 103: Rest of the World, Vaccines Market Forecast (In Percent), By Patient Type, 2020-2028
  • Figure 104: Vaccines Market Forecast (Technology wise in USD Billion), Global, 2018-2028
  • Figure 105: Vaccines Market Forecast (Technology wise In Percent), Global, 2020-2028
  • Figure 106: Conjugate Vaccines Market Forecast (Type wise in USD Billion), Global, 2020
  • Figure 107: Conjugate Vaccines, Vaccines Market Forecast (In Percent), By Type, 2020-2028
  • Figure 108: Inactivated and subunit Vaccines Market Forecast (Type wise in USD Billion), Global, 2020
  • Figure 109: Inactivated and subunit Vaccines, Vaccines Market Forecast (In Percent), By Type, 2020-2028
  • Figure 110: Live attenuated Vaccines, Market Forecast (Type wise in USD Billion), Global, 2020
  • Figure 111: Live attenuated Vaccines, Vaccines Market Forecast (In Percent), By Type, 2020-2028
  • Figure 112: Recombinant Vaccine Market Forecast (Type wise in USD Billion), Global, 2020
  • Figure 113: Recombinant Vaccine, Vaccines Market Forecast (In Percent), By Type, 2020-2028
  • Figure 114: Toxoid Vaccines Market Forecast (Type wise in USD Billion), Global, 2020
  • Figure 115: Toxoid Vaccines, Vaccines Market Forecast (In Percent), By Type, 2020-2028
  • Figure 116: Conjugate Vaccines Market Forecast (Mode of Administration wise in USD Billion), Global, 2020
  • Figure 117: Conjugate Vaccines, Vaccines Market Forecast (In Percent), By Mode of Administration, 2020-2028
  • Figure 118: Inactivated and subunit Vaccines Market Forecast (Mode of Administration wise in USD Billion), Global, 2020
  • Figure 119: Inactivated and subunit Vaccines, Vaccines Market Forecast (In Percent), By Mode of Administration, 2020-2028
  • Figure 120: Live attenuated, Market Forecast (Mode of Administration wise in USD Billion), Global, 2020
  • Figure 121: Live attenuated, Vaccines Market Forecast (In Percent), By Mode of Administration, 2020-2028
  • Figure 122: Recombinant Vaccine Market Forecast (Mode of Administration wise in USD Billion), Global, 2020
  • Figure 123: Recombinant Vaccine, Vaccines Market Forecast (In Percent), By Mode of Administration, 2020-2028
  • Figure 124: Toxoid Vaccines Market Forecast (Mode of Administration wise in USD Billion), Global, 2020
  • Figure 125: Toxoid Vaccines, Vaccines Market Forecast (In Percent), By Mode of Administration, 2020-2028
  • Figure 126: Vaccines Market Forecast (Source wise in USD Billion), Global, 2018-2020
  • Figure 127: Vaccines Market Forecast (End-Use Industry wise In Percent), Global, 2020-2028
  • Figure 128: Pediatic Patients Vaccines Market Forecast (Technology wise in USD Billion), Global, 2020
  • Figure 129: Pediatic Patients, Vaccines Market Forecast (In Percent), By Technology, 2020-2028
  • Figure 130: Adult Patients Market Forecast (Technology wise in USD Billion), Global, 2020
  • Figure 131: Adult Patients, Vaccines Market Forecast (In Percent), By Technology, 2020-2028
  • Figure 132: Pediatic Patients Market Forecast (Mode of Administration wise in USD Billion), Global, 2020
  • Figure 133: Pediatic Patients Market Forecast (In Percent), By Mode of Administration, 2020-2028
  • Figure 134: Adult Patients Market Forecast (Mode of Administration wise in USD Billion), Global, 2020
  • Figure 135: Adult Patients Market Forecast (In Percent), By Mode of Administration, 2020-2028
  • Figure 136: Global Vaccines Market (USD Billions), Corona Impact, 2020-2028
  • Figure 137: Global Vaccines Market (USD Billions), Corona Impact, 2020-2028
  • Figure 138: Global Vaccines Market (USD Billions), Revenue Impact due to Corona on Vaccines Market, 2020-2028
  • Figure 139: Global Vaccines Market (USD Billions), Corona Impact CS-1, 2020-2028
  • Figure 140: Global Vaccines Market (USD Billions), Corona Impact CS-2, 2020-2028
  • Figure 141: Global Vaccines Market (USD Billions), Corona Impact CS-3, 2020-2028
  • Figure 142: Vaccines market (In USD Billion), Scenario Analysis, 2020-2028
  • Figure 143: Vaccines market (In USD Billion), Scenario 1 Analysis, 2020-2028
  • Figure 144: Vaccines market (In USD Billion), Scenario 1 Type wise Analysis, 2020-2028
  • Figure 145: Vaccines market (In USD Billion), Scenario 2 Analysis, 2020-2028
  • Figure 146: Vaccines market (In USD Billion), Scenario 2 Industry wise Analysis, 2020-2028
  • Figure 147: Global Vaccines Market Forecast (In USD Billion), 2020-2028
  • Figure 148: Global Vaccines Market CAGR (In Percentage), 2020-2028
  • Figure 149: Global Vaccines Market Forecast (In USD Billion), 2020-2028
  • Figure 150: Global Vaccines Market CAGR (In Percentage), 2020-2028
  • Figure 151: Global Vaccines Market Forecast (In USD Billion), 2020-2028
  • Figure 152: Global Vaccines Market CAGR (In Percentage), 2020-2028
  • Figure 153: Pfizer Company Revenue of 2019,Global Vaccines Market, 2020-2028
  • Figure 154: Pfizer Company Revenue 2015 - 2019 (USD Billions)
  • Figure 155: Pfizer Company Profit 2015 - 2019 (USD Billions)
  • Figure 156: Sanofi Revenue of 2018,Global Personal Protective Market Market, 2020-2028
  • Figure 157: Sanofi Revenue 2015 - 2019 (USD Billions)
  • Figure 158: Sanofi Profit 2015 - 2019 (USD Billions)
  • Figure 159: GlaxoSmithKline Company Revenue of 2019,Global Vaccines Market, 2020-2028
  • Figure 160: GlaxoSmithKline Company Revenue 2015 - 2019 (USD Billions)
  • Figure 161: GlaxoSmithKline Company Profit 2015 - 2019 (USD Billions)
  • Figure 162: Johnson & Johnson Company Revenue of 2018,Global Vaccines Market, 2020-2028
  • Figure 163: Johnson & Johnson Company Revenue 2015 - 2019 (USD Billions)
  • Figure 164: Johnson & Johnson Company Profit 2015 - 2019 (USD Billions)
  • Figure 165: Merck Company Revenue of 2018,Global Vaccines Market, 2020-2028
  • Figure 166: Merck & Co. Company Revenue 2015 - 2019 (USD Millions)
  • Figure 167: Merck & Co. Company Profit 2015 - 2019 (USD Millions)
  • Figure 168: Novavax Company Revenue 2015 - 2019 (USD Billions)
  • Figure 169: CSL Limited Company Revenue 2015 - 2019 (USD Billions)
  • Figure 170: CSL Limited Company Profit 2015 - 2019 (USD Billions)
  • Figure 171: AstraZenca Company Revenue of 2018,Global Vaccines Market, 2020-2028
  • Figure 172: AstraZeneca Company Revenue 2017 - 2019 (USD Billions)
  • Figure 173: AstraZeneca Company Profit 2017 - 2019 (USD Billions)
  • Figure 174: Inovio Pharmaceuticals Company Revenue 2015 - 2019 (USD Billions)
  • Figure 175: Inovio Pharmaceuticals Company Profit 2015 - 2019 (USD Billions)
  • Figure 176: Emergent BioSolutions Company Revenue 2015 - 2019 (USD Billions)
  • Figure 177: Emergent BioSolutions Company Profit 2015 - 2019 (USD Billions)

Companies Listed

  • Pfizer
  • Sanofi
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • Merck & Co.
  • Novavax
  • CSL Limited
  • AstraZeneca
  • Inovio Pharmaceuticals
  • Emergent BioSolutions
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.